



## The Low Dose 3D™ Mammogram

Multiple studies show comparable performance to 3D Mammograms.



**Similar Performance**  
to FFDM 2D+  
Tomosynthesis<sup>1-4</sup>



**Increased invasive cancer detection**<sup>2-6</sup>



**Reduction in recall rates**<sup>2,5,8</sup>



**Consistently higher rate of cancers per recall**<sup>2,5,8</sup>

**Improved rate of cancers per biopsy**<sup>2,5,8</sup>



**Superior diagnostic accuracy**<sup>2,4,5,6,9,10</sup>



**Fast, 3.7 second scan time**, minimizes compression time and increases patient comfort



**Low patient dose** comparable to 2D exams—below the safe level set by the FDA<sup>2,3,7</sup>



## THE BENEFITS

Hologic's Low Dose 3D MAMMOGRAPHY™ exam powered by C-View™ software is proven clinically to increase invasive cancer detection<sup>2-6</sup> and decrease recall rates<sup>2,4,5,7,8</sup> compared with 2D alone, just like our original 3D Mammogram. C-View software progresses early breast cancer detection further by generating a 2D image directly from the tomosynthesis data, lowering patient radiation dose and compression time, with the added benefit of greater patient comfort.

GR-00953 © 2016 Hologic, Inc. Hologic, 3D Mammography, C-View, Dimensions, The Science of Sure, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the US and/or other countries.

<sup>1</sup>Zuckerman S, Conant E, Keller B, et al. "Implementation of Synthesized Two-dimensional Mammography in a Population-based Digital Breast Tomosynthesis Screening Program." *Radiology*, 10,1148/radiol.2016160366. <sup>2</sup>FDA PMA submission P080003/S001, physician labeling. <sup>3</sup>Skaane P, Bandos AI, Eben EB, et al. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. *Radiology*, 2014 Jun;271(3):655-63. <sup>4</sup>Bernardi D, Macaskill P, Pellegrini M et al. "Breast Cancer Screening with Tomosynthesis with Acquired or Synthetic 2D Mammography Alone (STORM-2): A Population-Based Prospective Study" *Lancet Oncology*. epub 2016 Jun 23. <sup>5</sup>Durand M, Raghu M, Geisel J, et al. "Synthesized 2D Mammography + Tomosynthesis: Can We See Clearly?" *Radiological Society of North America*, Chicago, IL, December 2015. <sup>6</sup>Choi J, Han B, Ko E, et al. "Comparison with Two-Dimensional Synthetic Mammography Reconstructed from Digital Breast Tomosynthesis and Full Field Digital Mammography for the Detection of T1 Breast Cancer." *European Radiology*. Epub 2015 Dec. <sup>7</sup>Zuley M, Guo B, Catullo V, et al. "Comparison of Two-dimensional Synthesized Mammograms versus Original Digital Mammograms Alone and in Combination with Tomosynthesis Images." *Radiology*, 2014 Jun;271(3):664-71. Epub 2014 Jan 21. <sup>8</sup>Zuckerman S, Conant E, Weinstein S, et al. "Impact on Recall Rates Following Implementation of Synthesized 2D Mammography in Digital Breast Tomosynthesis Screening." *Radiological Society of North America*, Chicago, IL, December 2015. <sup>9</sup>Woo O, Choi G, Shin H, et al. "Comparative Diagnostic Value of Two-dimensional Synthesized Mammogram and Conventional Full-field Digital Mammogram for Evaluation of Breast Cancer" *Radiological Society of North America*, Chicago, IL, December 2015. <sup>10</sup>Mariscotti G, Durando M, Bogetti C, et al. "Synthesized Digital Mammography Compared to Conventional Digital Mammography in a Diagnostic Setting" *Radiological Society of North America*, Chicago, IL, December 2015.

PPV: Positive Predictive Value